[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1286964T3 - Heterocykliske inhibitorer glycogensynthasekinase GSK-3 - Google Patents

Heterocykliske inhibitorer glycogensynthasekinase GSK-3

Info

Publication number
DK1286964T3
DK1286964T3 DK01928117T DK01928117T DK1286964T3 DK 1286964 T3 DK1286964 T3 DK 1286964T3 DK 01928117 T DK01928117 T DK 01928117T DK 01928117 T DK01928117 T DK 01928117T DK 1286964 T3 DK1286964 T3 DK 1286964T3
Authority
DK
Denmark
Prior art keywords
glycogen synthase
synthase kinase
disease
heterocyclic inhibitors
gsk
Prior art date
Application number
DK01928117T
Other languages
English (en)
Inventor
Martin Maria Concepcion Perez
Jurado Francisco Wandosell
Gil Ana Martinez
Morera Ana Castro
Mercedes Alonso Cascon
Isabel Dorronsoro Diaz
Munoz Francisco Jose Moreno
Original Assignee
Univ Madrid Autonoma
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200001185A external-priority patent/ES2166328B1/es
Application filed by Univ Madrid Autonoma, Consejo Superior Investigacion filed Critical Univ Madrid Autonoma
Application granted granted Critical
Publication of DK1286964T3 publication Critical patent/DK1286964T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK01928117T 2000-05-11 2001-05-11 Heterocykliske inhibitorer glycogensynthasekinase GSK-3 DK1286964T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200001185A ES2166328B1 (es) 2000-05-11 2000-05-11 Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en) 2000-05-11 2000-12-12 Enzyme inhibitors
PCT/GB2001/002100 WO2001085685A1 (en) 2000-05-11 2001-05-11 Heterocyclic inhibitors of glycogen synthase kinase gsk-3

Publications (1)

Publication Number Publication Date
DK1286964T3 true DK1286964T3 (da) 2007-10-01

Family

ID=26156184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928117T DK1286964T3 (da) 2000-05-11 2001-05-11 Heterocykliske inhibitorer glycogensynthasekinase GSK-3

Country Status (19)

Country Link
US (3) US6872737B2 (da)
EP (1) EP1286964B1 (da)
KR (1) KR100812407B1 (da)
CN (1) CN100358867C (da)
AT (1) ATE366238T1 (da)
AU (1) AU783615B2 (da)
BR (1) BR0110734A (da)
CA (1) CA2408747C (da)
CY (1) CY1106826T1 (da)
CZ (1) CZ296087B6 (da)
DE (1) DE60129222T2 (da)
DK (1) DK1286964T3 (da)
ES (1) ES2288948T3 (da)
HU (1) HUP0302002A3 (da)
IL (1) IL152721A0 (da)
MX (1) MXPA02011079A (da)
PL (1) PL209780B1 (da)
RU (1) RU2294931C2 (da)
WO (1) WO2001085685A1 (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110734A (pt) * 2000-05-11 2003-02-04 Consejo Superior Investigacion Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
WO2003018554A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
WO2003018011A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
US20050202559A1 (en) * 2002-10-29 2005-09-15 Scott Pownall Cancer treatment by metabolic modulations
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
GB0327908D0 (en) * 2003-12-02 2004-01-07 Neuropharma Sa GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
EP1574499A1 (en) * 2004-03-08 2005-09-14 DKFZ Deutsches Krebsforschungszentrum Inhibitors of DNA methylation in tumor cells
EP1586318A1 (en) * 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors
US8771754B2 (en) * 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) * 2004-10-21 2006-05-04 Neuropharma, S.A. The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
WO2006073364A1 (en) * 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
WO2006073363A1 (en) * 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
EP1846406B9 (en) 2005-02-09 2012-01-11 ArQule, Inc. Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
ES2258406B1 (es) * 2005-02-10 2007-12-01 Neuropharma, S.A. Uso de compuestos heterociclicos como agentes neurogenicos.
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
JP2009543874A (ja) * 2006-07-18 2009-12-10 ユニバーシティー オブ ロチェスター チアゾリジノン誘導体
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008057930A2 (en) 2006-11-02 2008-05-15 Aestus Therapeutics, Inc. Methods of treating neuropathic pain with retinoic acid receptor agonists
JP5425060B2 (ja) 2007-06-22 2014-02-26 アークル インコーポレイテッド ピロリジノン、ピロリジン−２，５−ジオン、ピロリジンおよびチオスクシンイミド誘導体、癌の治療のための組成物および方法
BRPI0813355A2 (pt) 2007-06-22 2014-12-30 Arqule Inc Compostos de quinazolinona e métodos de uso dos mesmos
ATE522531T1 (de) 2007-06-22 2011-09-15 Arqule Inc Indolylpyrrolidine zur behandlung von krebs
CN102137592B (zh) * 2008-06-16 2015-01-28 田纳西大学研究基金会 用于治疗癌症的化合物
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) * 2009-04-01 2011-07-20 深圳市盛捷生物技术有限公司 用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
ITNA20090047A1 (it) * 2009-07-16 2011-01-17 Adele Bolognese Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
EP2515914A4 (en) * 2009-12-23 2013-09-11 Scripps Research Inst BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
KR101939704B1 (ko) 2010-03-01 2019-01-17 지티엑스, 인코포레이티드 암 치료용 화합물
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
MY165634A (en) 2010-12-01 2018-04-18 Nissan Chemical Ind Ltd Pyrazole compounds having therapeutic effect on multiple myeloma
US11068954B2 (en) 2015-11-20 2021-07-20 Voicemonk Inc System for virtual agents to help customers and businesses
WO2012149335A2 (en) * 2011-04-28 2012-11-01 Richard Neubig Small molecule inhibitors of rgs proteins
EP2527323A1 (en) 2011-05-24 2012-11-28 Noscira, S.A. Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US9371299B2 (en) 2012-02-24 2016-06-21 Asd Therapeutics Partners, Llc Thiadiazolidinediones as GSK-3 inhibitors
CN103992312A (zh) * 2013-02-18 2014-08-20 江苏欧威医药有限公司 1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
EP4056677A1 (en) 2013-03-14 2022-09-14 The Brigham & Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion and culture
EA026332B1 (ru) 2013-03-14 2017-03-31 Общество с ограниченной ответственностью "Тиацен" Применение производных роданина для профилактики и/или лечения опухолевых заболеваний
WO2015017549A1 (en) * 2013-07-30 2015-02-05 University Of South Florida (A Florida Non-Profit Corporation) Treating an atypical protein kinase c enzyme abnormality
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
MX2017011820A (es) 2015-03-17 2018-03-15 Regeneron Pharma Reactivos de acilacion de aminoacidos y metodos para usar los mismos.
EP3400286A1 (en) 2016-01-08 2018-11-14 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
JP7109446B2 (ja) 2016-12-30 2022-07-29 フリークエンシー セラピューティクス インコーポレイテッド 幹細胞／前駆支持細胞の自己複製を誘導するための１ｈ－ピロール－２，５－ジオン化合物およびその使用方法
RU2761429C2 (ru) * 2018-06-13 2021-12-08 Общество с ограниченной ответственностью "Тиацен" Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
WO2020037323A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating jag-1
JP2022520671A (ja) 2019-02-08 2022-03-31 フリークエンシー・セラピューティクス・インコーポレイテッド 耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
CN110698380B (zh) * 2019-10-24 2021-01-15 华东理工大学 一种内酰胺衍生物及其制备方法与应用
WO2022170437A1 (en) * 2021-02-11 2022-08-18 Venca Research, Inc. Compositions and methods for treating arrhythmogenic cardiomyopathy
WO2022243973A1 (en) 2021-05-21 2022-11-24 Amo Pharma Ltd. Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en) 2021-05-24 2022-11-30 Consejo Superior De Investigaciones Científicas Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN116675653B (zh) * 2022-07-22 2024-10-01 中国药科大学 氨基烷基取代的1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2863803A (en) 1957-05-13 1958-12-09 Stauffer Chemical Co Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en) * 1964-11-16 1967-01-31 Olin Mathieson S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de) 1966-05-23 1970-11-12 Bayer Ag Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en) 1967-02-10 1975-08-19 Velsicol Chemical Corp New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en) * 1968-05-28 1970-10-13 Velsicol Chemical Corp Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de) 1971-03-02 1972-09-07 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Substituierte Thiadiazolidindione
US4183816A (en) * 1978-11-01 1980-01-15 Olin Corporation Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja) 1982-06-10 1983-12-15 Sumitomo Chem Co Ltd フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
ATE456367T1 (de) * 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
JP3714685B2 (ja) * 1994-05-18 2005-11-09 第一サントリーファーマ株式会社 ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) * 1994-06-13 1995-12-14 Bayer Ag Bakterizide Thiadiazolidinone
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
GB9918180D0 (en) * 1999-08-02 1999-10-06 Smithkline Beecham Plc Novel compositions
BR0110734A (pt) 2000-05-11 2003-02-04 Consejo Superior Investigacion Inibidores heterocìclicos de cinase de sintase de glicogênio gsk-3
GB0012056D0 (en) 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
EP1586318A1 (en) 2004-04-05 2005-10-19 Neuropharma S.A.U. Thiadiazolidinones as GSK-3 inhibitors

Also Published As

Publication number Publication date
KR100812407B1 (ko) 2008-03-11
US7781463B2 (en) 2010-08-24
CN1568310A (zh) 2005-01-19
US20080033012A1 (en) 2008-02-07
CZ296087B6 (cs) 2006-01-11
ATE366238T1 (de) 2007-07-15
ES2288948T3 (es) 2008-02-01
US6872737B2 (en) 2005-03-29
CA2408747A1 (en) 2001-11-15
AU5498101A (en) 2001-11-20
HUP0302002A3 (en) 2007-02-28
US7666885B2 (en) 2010-02-23
CZ20023692A3 (cs) 2003-06-18
CY1106826T1 (el) 2012-05-23
DE60129222D1 (de) 2007-08-16
AU783615B2 (en) 2005-11-17
WO2001085685A1 (en) 2001-11-15
EP1286964B1 (en) 2007-07-04
HUP0302002A2 (hu) 2003-09-29
CA2408747C (en) 2011-04-05
RU2294931C2 (ru) 2007-03-10
EP1286964A1 (en) 2003-03-05
IL152721A0 (en) 2003-06-24
DE60129222T2 (de) 2008-03-06
PL209780B1 (pl) 2011-10-31
PL359671A1 (en) 2004-09-06
KR20030025919A (ko) 2003-03-29
MXPA02011079A (es) 2004-08-19
US20050014803A1 (en) 2005-01-20
US20030195238A1 (en) 2003-10-16
CN100358867C (zh) 2008-01-02
BR0110734A (pt) 2003-02-04

Similar Documents

Publication Publication Date Title
DK1286964T3 (da) Heterocykliske inhibitorer glycogensynthasekinase GSK-3
DE60215814D1 (de) Vinylphenyl-derivate als glk-aktivatoren
SE0102300D0 (sv) Compounds
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
MY146279A (en) Compounds affecting glucokinase
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
ATE334973T1 (de) Chinazolinverbindungen
GB0112348D0 (en) Compounds
TW200716617A (en) Pyrazole compounds useful as protein kinase inhibitors
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
ATE466581T1 (de) Verbindungen auf pyrimidin-basis als gsk-3-hemmer
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
MXPA05013712A (es) Derivados de acido propionico, utiles en el tratamiento de trastornos de lipidos.
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
ATE409185T1 (de) Chinazolin derivate
WO2007012972A3 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
UA83691C2 (ru) Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона
MXPA05014201A (es) Pirazolo [3,4-b] piridin-6-onas como inhibidores de la gsk-3.
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
ATE279410T1 (de) 3-aminopyrazole als inhibitoren von cyclinabhängigen kinasen
ATE482955T1 (de) Azabicyclooctan-3-onderivate und deren verwendung
CA2534634A1 (en) Azolidinecarbonitriles and their use as dpp-iv inhibitors
WO2003080617A8 (en) Pyrazolopyrimidine derivatives